Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.70 |
| ▸ | TYMS | P04818 | 12/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.47 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442253 | 1.00 | PARP1 (0.70) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL9259148 | 0.82 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL30838794 | 0.82 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL29964360 | 0.79 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL12169915 | 0.79 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL30704850 | 0.79 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL2659299 | 0.79 | PARP1 (1.00) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL10227136 | 0.78 | PARP1 (0.68) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL19936540 | 0.77 | PARP1 (0.66) | PARP1TYMSTNKS2BMPR1BRAF1 | |
| SCHEMBL10361188 | 0.77 | PARP1 (0.66) | PARP1TYMSTNKS2BMPR1BRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105377831-B | Synthesis of 3- (5-amino-2-methyl-4-oxoquinazolin-3 (4H) -yl) piperidine-2, 6-dione | 细胞基因公司 | 2018-02-02 | — | — | CN | claimed |
| EP-3925609-A1 | METHODS OF TREATING MULTIPLE MYELOMA WITH IMMUNOMODULATORY COMPOUNDS IN COMBINATION WITH ANTIBODIES | Celgene Corporation (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-2943201-B1 | 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES | DEUTERX LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| CN-105377831-B | Synthesis of 3- (5-amino-2-methyl-4-oxoquinazolin-3 (4H) -yl) piperidine-2, 6-dione | 细胞基因公司 | 2018-02-02 | — | — | CN | disclosed |
| EP-3239144-A1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTI-CANCER AGENTS | Celgene Corporation (US) | 2017-11-01 | — | — | EP | disclosed |
| CN-107257800-A | Method for inducing target protein degradation by bifunctional molecules | 达纳-法伯癌症研究所股份有限公司 | 2017-10-17 | — | — | CN | disclosed |
| EP-2428513-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2420498-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2017027672-A1 | METHODS FOR TREATING SOLID TUMORS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO IMMUNOMODULATORY THERAPIES | CELGENE CORPORATION (US) | 2017-02-16 | — | — | WO | disclosed |
| WO-2016196580-A1 | METHODS FOR DETERMINING DRUG EFFICACY FOR TREATMENT OF CANCER USING RATIOS OF CEREBLON ASSOCIATED PROTEINS | CELGENE CORPORATION (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-2420497-B1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORP (US) | 2015-12-16 | — | — | EP | disclosed |
| WO-2014179661-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPY | CELGENE CORPORATION (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014172436-A1 | COMBINATION THERAPY COMPRISING A TOR KINASE INHIBITOR AND A 5-SUBSTITUTED QUINAZOLINONE COMPOUND FOR TREATING CANCER | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-10-23 | — | — | WO | disclosed |
| WO-2013106686-A1 | BIOMARKERS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | CELGENE CORPORATION (US) | 2013-07-18 | — | — | WO | disclosed |
| EP-2066656-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORP (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2428513-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2420497-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | CELGENE CORPORATION (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420498-A1 | 5-substituted quinazolinone derivatives as anti-cancer agents | Celgene Corporation (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2009075795-A1 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS | CELGENE CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008039489-A2 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS | CELGENE CORPORATION (US) | 2008-04-03 | — | — | WO | disclosed |